Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab Infusion Time Comparison in RA
NCT00887341Phase 2Completed
- Sponsor
- Roche
- Start
- May 2009
- Primary completion
- Dec 2010
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tocilizumab in rheumatoid arthritis (RA) (2 arms), sponsored by Roche. Primary endpoint: Percentage of Participants With an Infusion Reaction Within 24 Hours After Infusion. Started May 2009; status: completed.
02
Drugs
tocilizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00887341.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00887341.